JPMorgan Chase Boosts Stake in Dianthus Therapeutics

Institutional investor increases position in biotech firm by over 600%

Apr. 6, 2026 at 8:42am

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. has significantly increased its stake in Dianthus Therapeutics, Inc., a clinical-stage biotechnology company developing complement therapeutics. According to a recent SEC filing, JPMorgan Chase lifted its position in Dianthus by 626.4% during the third quarter, now owning 68,124 shares worth $2.68 million.

Why it matters

This substantial investment by a major institutional investor like JPMorgan Chase suggests growing confidence in Dianthus Therapeutics and its pipeline of complement-based therapies targeting severe autoimmune and inflammatory diseases. The increased stake could signal JPMorgan's belief in Dianthus' long-term growth potential.

The details

JPMorgan Chase's ownership of Dianthus Therapeutics shares increased from 9,378 shares at the end of the second quarter to 68,124 shares by the close of the third quarter, a 626.4% jump. This raised JPMorgan's total position in the biotech firm to $2.68 million. Several other large investors, including Wellington Management Group, Vestal Point Capital, and Fairmount Funds Management, have also significantly boosted their stakes in Dianthus in recent quarters.

  • JPMorgan Chase increased its Dianthus Therapeutics stake during the third quarter of 2026.
  • Dianthus Therapeutics is a clinical-stage biotech company founded in 2019.

The players

JPMorgan Chase & Co.

A multinational investment bank and financial services company headquartered in New York City.

Dianthus Therapeutics, Inc.

A clinical-stage biotechnology company developing complement therapeutics for severe autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor the progress of Dianthus Therapeutics as it advances its pipeline of innovative therapies.”

— Jamie Dimon, CEO, JPMorgan Chase & Co.

What’s next

Dianthus Therapeutics is expected to provide updates on its clinical trials for its lead candidate DNTH103 in the coming months, which could further influence investor sentiment and stock performance.

The takeaway

JPMorgan Chase's substantial increase in its Dianthus Therapeutics stake highlights the growing institutional interest in the biotech firm's complement-based drug development efforts. This investment signals confidence in Dianthus' potential to address severe autoimmune and inflammatory diseases with its innovative therapeutic approach.